Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia scheduled for heart transplantation
Clinical study published in Blood (2008)
Abstract
Anticoagulation management of patients with recent heparin-induced thrombocytopenia (HIT) requiring cardiopulmonary bypass (CPB) surgery is a serious challenge, and especially difficult in patients requiring urgent heart transplantation. As nonheparin anticoagulants during CPB bear a high risk of major bleeding, these patients are at risk of being taken off the transplant list. Short-term use of unfractionated heparin (UFH) for CPB, with restriction of UFH to the surgery itself, is safe and effective in patients with a history of HIT who test negative for antiplatelet factor 4 (PF4)/heparin antibodies. We present evidence that it is safe to expand the concept of UFH reexposure to patients with subacute HIT (ie, those patients with recent HIT in whom the platelet count has recovered but in whom anti-PF4/heparin IgG antibodies remain detectable) requiring heart transplantation, if they test negative by a sensitive functional assay using washed platelets. This can be lifesaving in patients with end-stage heart failure.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Demonstrates safety of restricted intraoperative heparin re-exposure (rather than alternative non-heparin anticoagulants with high bleeding risk) for heart-transplant patients with recent HIT testing negative on washed-platelet functional assays.
Por qué esto importa para la hirudoterapia
Este artículo presenta evidencia sobre el manejo de la anticoagulación en pacientes con trombocitopenia inducida por heparina (TIH) subaguda —definida como TIH reciente con recuentos plaquetarios recuperados pero anticuerpos IgG anti-PF4/heparina persistentemente detectables— que requieren trasplante cardíaco. Los autores argumentan que la heparina no fraccionada (HNF) a corto plazo, restringida exclusivamente a la cirugía de derivación cardiopulmonar, puede administrarse de forma segura en pacientes con TIH subaguda que dan negativo en un ensayo funcional sensible utilizando plaquetas lavadas, lo que resulta potencialmente salvavidas en la insuficiencia cardíaca terminal. Para la ASH, este resumen no contiene ninguna mención de hirudina, sanguijuelas, hirudoterapia ni el secretoma de la sanguijuela. El estudio aborda la estrategia de anticoagulación perioperatoria en cirugía de trasplante, y no puede establecerse ninguna conexión defendible con las terapéuticas basadas en sanguijuelas a partir del resumen.
Citación
Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia scheduled for heart transplantation.
Selleng S et al. · Blood, 2008
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026